MANE vs MRNA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MANE and MRNA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MANE and MRNA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Veradermics, Inc. (NYSE: MANE) is a New Haven, Connecticut biopharmaceutical company founded in 2019 and focused on dermatology and aesthetics. Its lead candidate, VDPHL01, is a proprietary oral, extended-release formulation of minoxidil designed to boost hair regrowth while limiting the cardiac exposure associated with existing oral minoxidil use. The company has completed enrollment in a roughly 519-patient Phase 2/3 study for male pattern hair loss that showed statistically significant hair-count gains versus placebo, and has additional registrational work underway: a confirmatory Phase 3 study in men ('304) with topline data expected in the second half of 2026, 12-month data from the '302 study on the same timeline, and a fully enrolled 556-patient registration-directed study in women ('306) with topline data expected in the first half of 2027. An open-label Phase 2 study in women ('207) reported positive six-month hair-count results in July 2026. A smaller pipeline includes VDMN (a dissolvable microarray patch for common warts), VDAA (alopecia areata), and VDMC (molluscum contagiosum).

Full MANE guide

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

Full MRNA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MANE drivers: Large, underserved hair-loss market; Statistically significant lead-asset data.
• MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Veradermics is pre-revenue and has no approved product, so it generates ongoing net losses (about $104 million on a trailing basis as of mid-2026) and depends on clinical and regulatory success it has not yet achieved. For MRNA, revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MANE if you believe its drivers more; MRNA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MANE and MRNA guides.

MANE. Traditional valuation multiples do not apply because Veradermics has no product revenue and posts consistent losses; the roughly $4.5 billion market value reflects expectations for VDPHL01 rather than current financials. About $820 million of cash covers a meaningful share of that value, so the market is assigning roughly $3.7 billion to the pipeline ahead of registrational readouts. The stock has swung across a 52-week range of roughly $32 to $137 since its February 2026 IPO at $17, and six covering analysts average a target near $163.50.

MRNA. MRNA trades on pipeline potential rather than current earnings: it is loss-making, revenue is far below its pandemic peak, and P/E is not meaningful. What changed in 2026 is the price of that option, with the stock up about 590% year to date to roughly 38 times trailing sales after the August Phase 3 melanoma success. The 18 analysts Yahoo Finance tracks have a mean target near $124, well under the $213 close, so the detailed data later in October and the November 6 Q3 report (consensus revenue near $892 million, EPS near -$1.30) carry unusual weight.

Headline figures (approximate, October 2026): MANE shows revenue (ttm) ~$0 (pre-commercial), net loss (ttm) ~$104M; Q2 2026 ~$23.5M, eps Q2 2026 ~$(0.58) vs ~$(0.64) consensus; trailing ~$(4.24), cash & securities ~$820M at Jun 30, 2026; runway guided into 2030; MRNA shows market cap ~$85 billion, revenue (ttm) ~$2.2 billion, q2 2026 revenue ~$145 million, net income (ttm) ~-$3.2 billion.

MANE and MRNA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MANE and MRNA exposure against your real portfolio. It is not an investment adviser.